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Rheumatic heart disease in Africa: the Mosi-o-Tunya call 
to action
Rheumatic heart disease is a neglected post-infectious 
chronic disease of children and young adults that 
continues to maim and kill millions of people needlessly. 
Sub-Saharan Africa is the hotspot of the world, with a 
prevalence of 5·7 per 1000 in children aged 5–14 years 
in 2005.1 This information galvanised the Pan African 
Society of Cardiology (PASCAR), together with the WHO 
Regional Oﬃ  ce for Africa (WHO-AFRO), the World Heart 
Federation, and the South African National Department 
of Health to convene the ﬁ rst All-Africa Workshop 
on rheumatic fever and rheumatic heart disease on 
Oct 15–16, 2005, near Drakensberg in South Africa.2 
The intensive deliberations that ensued resulted in 
the adoption of the Drakensberg Declaration on the 
control of rheumatic fever and rheumatic heart disease 
in Africa, a clarion call for the establishment of national 
programmes to prevent rheumatic fever and rheumatic 
heart disease in all African countries.3 
In the past decade, the Drakensberg Declaration has 
spawned a series of studies that have shown that the 
burden of rheumatic heart disease is much higher than 
estimated in 2005. An inﬂ uential echocardiography 
screening study4 showed that the prevalence of 
rheumatic heart disease among school children was 
30 per 1000 (95% CI 23 to 38) in Mozambique. The high 
prevalence in asymptomatic school children in the sub-
Saharan African region was subsequently conﬁ rmed 
in Uganda where the rate was reported to be 15 per 
1000 children (95% CI 7 to 22).5 Although no population-
based studies of the incidence of acute rheumatic fever 
have been reported from Africa,6 the incidence of heart 
failure due to rheumatic heart disease remains high.7,8 In 
Soweto near Johannesburg, the industrial hub of South 
Africa where a low burden of rheumatic heart disease 
might be expected owing to better socioeconomic 
conditions,9 the incidence of heart failure due to 
rheumatic heart disease ranges from 30 per 100 000 per 
year in individuals aged 14–19 years to 53 per 100 000 per 
year in people 60 years or older (ﬁ gure).7 The sub-Saharan 
Africa Survey of Heart Failure (THESUS-HF) registry 
of 1006 patients with heart failure from nine African 
countries shows that rheumatic heart disease is the third 
most important cause of heart failure in adult Africans, 
accounting for 14·3% of cases.8 The most worrying 
ﬁ nding has been the high morbidity and mortality 
associated with rheumatic heart disease in pregnancy. 
A study10 from Senegal showed that rheumatic heart 
disease is associated with a maternal mortality rate of 
34% in pregnancy and a high rate of fetal loss among 
survivors. Therefore, the high burden of rheumatic heart 
disease in sub-Saharan Africa undermines eﬀ orts to 
achieve the Millennium Development Goals.
Although much has been achieved over the past 
10 years in terms of improved understanding of the high 
burden and poor outcomes associated with rheumatic 
heart disease in sub-Saharan Africa, little progress has 
been made in terms of establishing national prevention 
policies and programmes. It is therefore timely that 
PASCAR, in conjunction with WHO-AFRO, convened 
the 2nd All-Africa Workshop on Rheumatic Fever and 
Rheumatic Heart Disease in Livingstone, Zambia, on 
Feb 1–2, 2014, to review progress and chart the way 
forward for the control of rheumatic heart disease in 
Africa. At the workshop, the failure to eliminate rheumatic 
heart disease was recognised as being related partly to the 
poor treatment of Streptococcus pharyngitis with penicillin 
in primary care in many African countries.11 Furthermore, 
a virtual absence was noted of register-based secondary 
prevention programmes in African countries. 
An urgent need therefore exists for ministries of health 
to introduce programmes for the primary and secondary 
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Figure: Incidence of heart failure due to rheumatic heart disease in Soweto, 
South Africa7 
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prevention of rheumatic heart disease through their 
non-communicable disease programmes. The delivery 
of penicillin for the treatment of sore throat in children 
and the prevention of recurrent attacks of rheumatic 
fever in aﬀ ected individuals is the central intervention 
needed to eliminate rheumatic fever and control 
rheumatic heart disease.12 PASCAR and WHO-AFRO have 
issued the Mosi-o-Tunya Call to Action13 to governments 
in endemic countries to ensure that the scourge of 
rheumatic heart disease is eliminated in our lifetimes.
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